Clinical trials: Perimenopausal Bone Loss
Osteoporosis, Postmenopausal
Health Literacy's Impact on Exercise Habits and Medication Adherence in Postmenopausal Osteoporosis
Postmenopausal osteoporosis is characterized by low bone mass and increased fracture risk. Treatment includes exercise, nutrition, supplements, and medications like bisphosphonates, denosumab, or hormone replacement therapy.
- Trial name
- NCT06462833
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Gazi University
Osteoporosis in Post-menopausal Women
Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures
The aim of this clinical trial is to investigate the effectiveness of romosozumab started without stopping denosumab in patients diagnosed with postmenopausal osteoporosis with a very high risk of fragility fractures and who is…
- Trial name
- MORD (NCT06720350)
- Testing
- Romosozumab and Denosumab Combination Therapy, Romosozumab Prefilled Syringe [Evenity], Denosumab (Prolia)
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Marmara University
Postmenopausal Osteoporosis
A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
This single arm study will assess the efficacy and safety of quarterly intravenous Bonviva in women with post-menopausal osteoporosis. All patients will receive Bonviva 3mg i.v. every 3 months.
- Trial name
- NCT00493532
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 14 sites in Taiwan
- Sponsor
- Hoffmann-La Roche
Osteoporosis, Postmenopausal
Effect of Mechanical Loading With PTH on Cortical Bone
Clinical trial to investigate effect of voluntary upper extremity loading in combination with anabolic osteoporosis therapy.
- Trial name
- NCT03232476
- Testing
- Upper extremity voluntary loading
- Volunteers
- healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Osteoporosis, Osteoporosis, Postmenopausal
Effect of Focal Vibration Within a Multicomponent Exercise Program for Older Women With Osteoporosis a Single-blind Clinical Trial
The high annual incidence of osteporosis and its high prevalence , means that more and more resources are being devoted to its diagnosis, prevention and treatment in primary care.
- Trial name
- NCT05538377
- Testing
- Focal Vibration, Control Group
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Universitat Internacional de Catalunya
Osteoporosis
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of 3 doses of ALX1-11 (recombinant human parathyroid hormone [rhPTH(1-84)])(50, 75 and 100 µg) in the treatment of postmenopausal…
- Trial name
- NCT00172107
- Testing
- ALX1-11 50 mcg, ALX1-11 75mcg, ALX1-11
- Where
- 19 sites in United States, Canada
- Volunteers
- 217 people
- Sponsor
- Shire
Postmenopausal Osteoporosis, Hypovitaminosis D
Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients
Osteoporosis is defined as a systemic disease of bone mineralization, characterized by a decrease in bone mineral density that causes bone fragility and increases the risk of fractures during menopause.
- Conditions
- Postmenopausal Osteoporosis, Hypovitaminosis D, Hyperparathyroidism
- Trial name
- NCT05346419
- Testing
- Risedronate, Vitamin D
- Where
- Mexico
- Volunteers
- 33 people
- Sponsor
- Hospital Regional 1o de Octubre
Osteoporosis, Postmenopausal
Hesperidin and Bone Health in Postmenopausal Women
The primary objective of this clinical trial is to test hesperidin with and without CALCILOCK® for bone resorption suppressing effect in postmenopausal women.
- Trial name
- Hesperidin (NCT01881204)
- Testing
- Hesperidin and Calcilock, Hesperidin, Control
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Purdue University
Postmenopausal Women With Osteoporosis
Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis
This study was conducted to assess if there were any clinically meaningful differences in pharmacokinetics (PK), pharmacodynamics (PD), efficacy, safety, or immunogenicity between GP2411 (proposed biosimilar denosumab) and…
- Trial name
- NCT03974100
- Testing
- GP2411, EU-Prolia (EU-authorized Prolia®)
- Where
- 42 sites in United States, Bulgaria and 4 more
- Volunteers
- 527 people
- Sponsor
- Sandoz
Perimenopausal Bone Loss
Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss
This is a study to determine if Fosamax (alendronate), a medication approved by the Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in postmenopausal women, is effective in decreasing the rate…
- Trial name
- NCT00221312
- Testing
- Fosamax
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Bone and Bones, Osteoporosis Risk
Milk Protein and Bone Health in Postmenopausal Women
The process of bone remodeling exhibits pronounced diurnal pattern that is important for bone health. A balanced rate of bone resorption is required to maintain bone health, a balance that can be disturbed during the life-cycle…
- Conditions
- Bone and Bones, Osteoporosis Risk, Osteoporosis, Postmenopausal
- Trial name
- OSTEOMILK (NCT03701113)
- Testing
- Milk-based protein matrix (MBPM), Habitual dietary behaviour
- Where
- Ireland
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of Limerick
Osteoporosis
A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients
This is a Multi-Center, Randomized, Double-Blind, Dose Escalation, Placebo Parallel Controlled PhaseⅠClinical study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics, Immunogenicity with Multiple…
- Trial name
- NCT04435158
- Testing
- SHR-1222
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Osteoporosis, Postmenopausal
The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women
This is an observational study to investigate the prevalence of osteoporotic fractures in post menopausal patients. Post menopausal patients who visit OS(orthopedic surgery) including GHs(general hospitals) and clinics will be…
- Trial name
- TOP (NCT01381588)
- Testing
- Fracture evaluation
- Where
- South Korea
- Volunteers
- 1,136 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Postmenopausal Osteoporosis, Postmenopausal Osteopenia
The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation
This study is a prospective, multicenter, open-label, randomized non-inferiority trial comparing intravenous ibandronate and zoledronic acid as sequential therapy after denosumab discontinuation in postmenopausal women with…
- Conditions
- Postmenopausal Osteoporosis, Postmenopausal Osteopenia, Primary Osteoporosis, Osteoporosis
- Trial name
- NCT07406685
- Testing
- Ibandronate IV, Zoledronic acid IV
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- National Taiwan University Hospital
Osteoporosis, Postmenopausal
Quercetin's Effect on Bone Health and Inflammatory Markers
Quercetin is a plant-based flavonoid that is naturally found in many fruits and vegetables, and is considered to be a potent antioxidant with several expected health benefits such as anti-inflammatory effects and bone-conserving…
- Trial name
- NCT05371340
- Testing
- Quercetin (500 mg)
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Kennesaw State University
Osteoporosis, Postmenopausal
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
The purpose of this study is to compare treatment with both teriparatide and raloxifene with teriparatide alone. The study will evaluate any side effects that may be associated with the two drugs and may help to determine whether…
- Trial name
- NCT00046137
- Testing
- teriparatide, raloxifene
- Where
- 13 sites in United States
- Sponsor
- Eli Lilly and Company
Osteoporosis, Postmenopausal
POWER Point of Care Effect on Satisfaction of Treatment
To compare the subject satisfaction rating in women treated for postmenopausal osteoporosis with Actonel 35mg Once-a-Week for 24 weeks, and receiving feedback information, after 12 weeks of treatment, based on bone resorption…
- Trial name
- NCT00549068
- Testing
- Risedronate Sodium (Actonel)
- Volunteers
- 2,433 people
- Sponsor
- Sanofi
Postmenopausal Osteoporosis
Resolution of Effect of Bisphosphonates on Bone in Postmenopausal Osteoporosis
This is a 2year observational study that will recruit patients who have previously completed a randomised, open label, parallel, single centre study (TRIO Study) of three bisphosphonates: alendronate, ibandronate and risedronate.
- Trial name
- NCT01406613
- Testing
- Observation
- Where
- United Kingdom
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Osteoporosis, Postmenopausal
Soluble Corn Fiber Effect on Bone Resorption in Post Menopausal Women
This study is designed to study the dose response effect of continuous Soluble Corn Fiber (SCF) intake over a 50 day period on bone resorption in healthy post menopausal women using the 41Calcium methodology.
- Trial name
- NCT02416947
- Testing
- 0 g SCF, 10g SCF, 20g SCF
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Purdue University
Post Menopausal Osteoporosis
DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
This study will assess the efficacy and safety of intravenous administration of Bonviva regimens in women with post-menopausal osteoporosis, compared to oral daily administration.
- Trial name
- NCT00048074
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 64 sites in United States, Australia and 14 more
- Volunteers
- 1,395 people
- Sponsor
- Hoffmann-La Roche